The COVID-19 pandemic continues to evolve and impact our personal and professional lives. We want to assure our trustees, reviewers, and grantee communities that our TMF staff continues to provide high quality biomedical research grantmaking services. We will do our part to help manage any potential challenges and continue supporting research to the extent that it is possible. Please notify us with any questions or requests.
HIGH-IMPACT, INNOVATIVE TRANSLATIONAL RESEARCH TO ADVANCE THE TREATMENT AND PREVENTION OF MDS
The Taub Foundation Grants Program for Myelodysplastic Syndromes (MDS) Research was created to support high-impact, innovative translational research to understand the underlying causes of MDS and to advance its treatment and prevention. The Program specifically focuses on MDS research, exclusive of AML and MPN. Studies focusing on molecular genetics, epigenetics, splicing factors, stem cells, the microenvironment and novel therapeutic targets relevant to MDS are encouraged.
Innovative studies with transformative potential to elucidate MDS etiology and to develop new treatments are particularly encouraged.
The Taub Program supports independent investigators at all stages of their careers. To promote the expansion of the MDS research field collaborative efforts and proposals from young investigators and those from non-MDS fields are encouraged to apply.
Three-year awards of $600,000 ($200,000 per year, inclusive of 10% indirect costs) will be made to independent investigators working in non-profit, non-governmental academic, medical, or research institutions within the United States. Collaborative efforts are encouraged.